Abiopharma

🔍 LAMACH MICHAEL W (Director)

Company: COLUMBUS MCKINNON CORP (CMCO)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 7,590 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,590.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: By trust | shares_owned_after: 255.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: By trust | shares_owned_after: 15.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: H | nature_of_ownership: By trust | shares_owned_after: 20.00 | Footnotes: F3

Footnotes:

• F1: Represents shares granted to reporting person under the Columbus McKinnon Corporation 2016 Long Term Incentive Plan as amended and restated effective June 4, 2024, and further amended effective August 14, 2026.
• F2: Reflects securities held by a grantor retained annuity trust. The reporting person serves as the sole trustee and the reporting person's estate is a beneficiary of the trust.
• F3: Reflects securities held by a revocable trust. The reporting person serves as the sole trustee and is the primary beneficiary of the trust.